New drug combo tested for aggressive, rare kidney cancer
NCT ID NCT03587662
Summary
This study is testing whether adding a new drug called ixazomib to two standard chemotherapy drugs works better for controlling an aggressive type of kidney cancer that has spread. It is for patients aged 12 and older whose cancer has progressed after other treatments and who have a specific genetic marker. The main goal is to see if the three-drug combination can shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.